PD-1/PD-L1抑制剂治疗非小细胞肺癌的疗效及预后观察

Therapeutic effect of PD-1/PD-L1 inhibitor in the treatment of non-small cell lung cancer and prognosis evaluation

目的评价纳武利尤单抗治疗一线化疗方案无效或复发的晚期非小细胞肺癌(NSCLC)患者的疗效及预后。方法将86例晚期NSCLC患者分为对照组(43例)和研究组(43例),对照组采用多西他赛化疗,研究组应用纳武利尤单抗治疗。比较两组患者的疗效、不良反应及生存情况。结果研究组患者的疗效明显优于对照组,差异有统计学意义(P﹤0.01)。研究组患者脱发、贫血、肌肉疼痛及中性粒细胞减少不良反应发生率均明显低于对照组,差异均有统计学意义(P﹤0.01)。对照组患者中位生存时间为4.200个月(95%CI:2.787~5.613),1年累积生存率为6.98%;研究组患者中位生存时间为2.800个月(95%CI:2.029~3.571),1年累积生存率为18.60%;Log-rank检验显示,两组患者生存情况比较,差异无统计学意义(P=0.792)。结论纳武利尤单抗安全性较好,可使一线化疗方案失败或复发的晚期NSCLC患者获益。

Objective To evaluate the efficacy and safety of nivolumab in patients with advanced non-small cell lung cancer(NSCLC)who were irresponsive to or relapsed after first-line chemotherapy.Method Altogether,86 patients with advanced NSCLC were included in the research as control group(n=43)and study group(n=43),respectively.The control group was treated with docetaxel,and the study group was given nivolumab.The efficacy,adverse reactions and overall survival of the two groups were compared.Result The overall response was significantly better in study group than in control group,there was significant difference observed(P<0.01).The incidence rates of alopecia,anemia,myalgia and neutropenia in study group were significantly lower compared to control group(P<0.01).The median survival time of control group was 4.200 months(95%CI:2.787-5.613),and the 1-year survival rate were 6.98%;the corresponding results in study group were 2.800 months(95%CI:2.029-3.571)and 18.60%,respectively.Log-rank test indicated no significant difference in regard to the survival between the two groups(P=0.792).Conclusion Nivolumab demonstrates high safety during administration,and benefits patients with advanced NSCLC who have failed first-line chemotherapy or relapsed diseases.